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The American College of Cardiology (ACC)/AmericanHeart Association (AHA) guidelines for the management
of unstable angina and non–ST-segment elevation myocardial
infarction (UA/NSTEMI) were published in September
2000.1 Since then, a number of clinical trials and observa-
tional studies have been published or presented that, when
taken together, alter significantly the recommendations made
in that document. Therefore, the ACC/AHA Committee on
the Management of Patients With Unstable Angina, with the
concurrence of the ACC/AHA Task Force on Practice Guide-
lines, revised these guidelines. These revisions were prepared
in December 2001, reviewed and approved, and then pub-
lished on the ACC World Wide Web site (www.acc.org) and
AHA World Wide Web site (www.americanheart.org) on
March 15, 2002. The present article describes these revisions
and provides further updates in this rapidly moving field.
Minor clarifications in the wording of three recommendations
that now appear differently from those that were previously
published on the ACC and AHA Web sites are noted in
footnotes.
The ACC/AHA classifications I, II, and III are used to
summarize indications as follows:
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Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or
treatment is useful and effective.
Class II: Conditions for which there is conflicting evi-
dence and/or a divergence of opinion about the
usefulness/efficacy of a procedure or treatment.
IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
IIb: Usefulness/efficacy is less well established
by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treat-
ment is not useful/effective and in some cases
may be harmful.
The weight of the evidence was ranked highest (A) if the
data were derived from multiple randomized clinical trials
that involved large numbers of patients and intermediate (B)
if the data were derived from a limited number of randomized
trials that involved small numbers of patients or from careful
analyses of nonrandomized studies or observational regis-
tries. A lower rank (C) was given when expert consensus was
the primary basis for the recommendation.
Risk Assessment
Clinical Features
Unstable angina and NSTEMI are heterogeneous disorders in
which patients have widely varying risks. Risk is an impor-
tant “driver” of management decisions, and accurate yet
simple methods of risk assessment are important for patient
care.
Risk was assessed by multivariable regression techniques
in patients presenting with UA/NSTEMI in several large
clinical trials. Boersma et al analyzed the relation between
baseline characteristics and the incidence of death and the
composite of death or myocardial (re)infarction at 30 days in
patients who entered the PURSUIT (Platelet IIb/IIIa in
Unstable angina: Receptor Suppression Using Integrilin
Therapy) trial.2 The most important baseline features associ-
ated with death were age, heart rate, systolic blood pressure,
ST-segment depression, signs of heart failure, and elevation
of cardiac biomarkers. From this analysis, a simple risk
estimation score was developed.
Antman et al developed a 7-point risk score, the “TIMI
Risk Score,” (age greater than or equal to 65 years, more than
3 coronary risk factors, prior angiographic coronary obstruc-
tion, ST-segment deviation, more than 2 angina events within
24 hours, use of aspirin (ASA) within 7 days, and elevated
cardiac markers).3 The score was defined as the simple sum of
these individual prognostic variables. The risk of developing
an adverse outcome—death, (re)infarction, or recurrent se-
vere ischemia that required revascularization—ranged from
5% with a score of 0 or 1 to 41% with a score of 6 or 7. The
score was derived from data in the TIMI 11B (Thrombolysis
In Myocardial Infarction 11B) trial4 and then validated in 3
additional trials—ESSENCE (Efficacy and Safety of Subcu-
taneous Enoxaparin in Non–Q-wave Coronary Events
study),5 and PRISM-PLUS (Platelet Receptor inhibition for
Ischemic Syndrome Management in Patients Limited by
Unstable Signs and symptoms)6 and prospectively in one
TACTICS-TIMI 18 (Treat angina with Aggrastat and deter-
mine Cost of Therapy with an Invasive or Conservative
Strategy–Thrombolysis In Myocardial Infarction) 18.7 A
progressively greater benefit from newer therapies such as
low-molecular-weight heparin (LMWH),4,5 platelet glycopro-
tein (GP) IIb/IIIa receptor antagonists,6 and an invasive
strategy7 with increasing risk score have been reported.
Biomarkers
The Joint European Society of Cardiology/American College
of Cardiology Committee for the Redefinition of Myocardial
Infarction8 emphasized the use of troponins as critical mark-
ers of the presence of myocardial necrosis. Although tro-
ponins are accurate in identifying myocardial necrosis, the
latter is not always secondary to atherosclerotic coronary
artery disease. Therefore, in establishing the diagnosis of
NSTEMI, cardiac troponins should be used in conjunction
with appropriate clinical features and electrocardiographic
changes. Myocardial injury of diverse origins (eg, myocardi-
tis, trauma, or cardioversion) may cause necrosis and release
of troponins. Although these may be considered instances of
NSTEMI, they should be distinguished on clinical grounds
from the more common form of NSTEMI secondary to
coronary atherosclerosis.
Antiplatelet Therapy
Antiplatelet therapy is a cornerstone in the management of
UA/NSTEMI. Three classes of antiplatelet drugs (ASA,
thienopyridines, and GP IIb/IIIa antagonists) have been found
useful in the management of these patients and are the subject
of continued intensive investigation and analysis.
Clopidogrel
Given its more rapid onset of action9,10 and better safety
profile compared with ticlopidine, clopidogrel is now the
preferred thienopyridine. The CURE (Clopidogrel in Unsta-
ble angina to prevent Recurrent ischemic Events) trial11
randomized 12 562 patients with UA/STEMI who presented
within 24 hours to placebo or clopidogrel (loading dose of
300 mg followed by 75 mg daily) and followed them for 3 to
12 months; all patients were given aspirin. Cardiovascular
death, myocardial infarction (MI), or stroke occurred in
11.5% of patients assigned to placebo and 9.3% of those
assigned to clopidogrel (relative risk [RR] 0.80; P less than
0.001). Looking at the individual components of the primary
composite and end point, there was a trend in favor of
clopidogrel for cardiovascular death and stroke (5.5% and
1.4%, respectively, for placebo vs 5.1% and 1.2% for clopi-
dogrel), and there was a significant reduction in MI (6.7% vs
5.2% RR  0.77, P less than 0.001). However, there was no
significant difference in the incidence of non–Q-wave MI
(3.8% vs 3.5%). A reduction in recurrent ischemia was noted
within the first few hours after randomization. These salutary
results were observed across all subgroups of patients. There
was, however, a significant excess of major bleeding (2.7% in
the placebo group versus 3.7% in the clopidogrel group; P
0.003) and of minor bleeding, as well as a (nonsignificant)
trend for an increase in life-threatening bleeding. The risk of
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bleeding was increased in patients who underwent coronary
artery bypass grafting (CABG) within the first 5 days after
clopidogrel was discontinued.
The CURE trial was performed in hospitals in which there
was no routine policy of early invasive procedures, and
therefore, revascularization was performed during the initial
admission in only 23% of the patients, a substantially lower
percentage than currently receive this therapy at most US
hospitals. Although the addition of a GP IIb/IIIa antagonist
appeared to be well tolerated in patients who were given
ASA, clopidogrel, and heparin in CURE, fewer than 10% of
patients received this combination. Therefore, additional
information on the safety of “quadruple therapy” (heparin
[unfractionated or low molecular weight], ASA, clopidogrel,
and a GP IIb/IIIa antagonist) should be obtained.
The CURE trial provides strong support for the addition of
clopidogrel to ASA on admission in the management of
patients with UA and NSTEMI. Clopidogrel appears to be
especially useful in hospitals that do not have a routine policy
of early invasive procedures and in patients who are not
candidates or who do not wish to be considered for revascu-
larization. The optimal duration of therapy with clopidogrel
has not been determined. The major benefits in CURE were
observed at 30 days, with small additional benefits observed
over the subsequent treatment period, which averaged 8
months.
In PCI-CURE, a substudy of CURE, 2658 patients who
underwent percutaneous coronary intervention (PCI) had
been randomly assigned to double-blind treatment with clo-
pidogrel (n1313) or placebo (n1345)12; all patients also
received ASA. Patients were pretreated with placebo or study
drug for a median of 10 days before PCI. After the procedure,
most patients received open-label thienopyridine (clopidogrel
or ticlopidine) for approximately 4 weeks, after which the
study drug (placebo or clopidogrel) was again administered
for an average of 8 months. The primary end point, a
composite of cardiovascular death, MI, or urgent target-
vessel revascularization within 30 days of PCI, occurred in 86
patients (6.4%) in the placebo group compared with 59
(4.5%) in the clopidogrel group (RR 0.70; P0.03). When
events that occurred before and after PCI were considered,
there was a 31% reduction in cardiovascular death or MI with
assignment to clopidogrel (P0.002). Thus, in patients with
UA and NSTEMI who are given ASA and are undergoing
PCI, a strategy of clopidogrel pretreatment followed by at
least 1 month and probably longer-term therapy is beneficial
in reducing major cardiovascular events.12
There now appears to be an important role for clopidogrel
in patients with UA/NSTEMI, both those who are managed
conservatively and those who undergo PCI, especially stent-
ing. However, it is not entirely clear how long therapy should
be maintained. Because clopidogrel, when added to ASA,
increases the risk of bleeding during major surgery in patients
who are scheduled for CABG, if possible, clopidogrel should
be withheld for at least 5 days11 and preferably for 7 days
before surgery.13 In many hospitals in which patients with
UA/NSTEMI undergo diagnostic catheterization within 24 to
36 hours of admission, clopidogrel is not started until it is
clear that CABG will not be scheduled within the next several
days. A loading dose of clopidogrel can be given to a patient
on the catheterization table if a PCI is to be performed
immediately. If PCI is not performed, clopidogrel can be
begun after the catheterization.
Glycoprotein IIb/IIIa Antagonists in PCI
The introduction of platelet GP IIb/IIIa antagonists represents
an important advance in the treatment of patients with
UA/NSTEMI who are undergoing PCI. These drugs take
advantage of the fact that platelets play an important role in
the development of ischemic complications that may occur in
patients with UA/NSTEMI during coronary revascularization
procedures. The September 2000 guidelines emphasized the
value of GP IIb/IIIa antagonists in patients with UA/NSTEMI
who were undergoing PCI.1
Two trials of GP IIb/IIIa inhibitors have been published
since September 2000. The ESPRIT trial (Enhanced Suppres-
sion of the Platelet IIb/IIIa Receptor with Integrilin Therapy)
was a placebo-controlled trial designed to assess whether
eptifibatide improved outcome in patients undergoing stent-
ing.14 Fourteen percent of the 2064 patients enrolled in
ESPRIT had UA/NSTEMI. The primary end point (the
composite of death, MI, target-vessel revascularization, and
“bailout” GP IIb/IIIa antagonist therapy) was reduced from
10.5% to 6.6% with treatment (P0.0015). There was con-
sistency in the reduction of events in all components of the
end point and in all major subgroups, including patients with
UA/NSTEMI. Major bleeding occurred more frequently in
patients who received eptifibatide (1.3%) than in those who
received placebo (0.4%; P0.027); however, no significant
difference in the transfusion rate occurred. At 1 year of
follow-up, death or MI occurred in 12.4% of patients as-
signed to placebo and 8.0% of eptifibatide-treated patients
(hazard ratio 0.63; 95% confidence interval [CI] 0.48 to 0.83;
P0.001).15
In the only head-to-head comparison of GP IIb/IIIa antag-
onists, the TARGET trial (Do Tirofiban and ReoPro Give
similar Efficacy? Trial) randomized 5308 patients to tirofiban
or abciximab before PCI with the intent to perform stenting.16
The primary end point, a composite of death, nonfatal MI,
and urgent target-vessel revascularization at 30 days, oc-
curred less frequently in those given abciximab than in those
given tirofiban (6.0% versus 7.6%; P0.038). There was a
similar direction and magnitude for each component of the
end point. The difference in outcome between the 2 treatment
groups may be related to a suboptimal dose of tirofiban
resulting in inadequate platelet inhibition. However, by six
months, the primary end point occurred in a similar percent-
age of patients in each group (14.9% tirofiban versus 14.3%
abciximab, NS). Mortality was also similar (1.9% versus
1.7%, NS).17
Glycoprotein IIb/IIIa Antagonists Without Scheduled PCI
The Global Utilization of Strategies to Open Occluded
Coronary Arteries IV-Acute Coronary Syndromes (GUSTO
IV-ACS) trial18 enrolled 7800 patients with UA/NSTEMI
who were admitted to the hospital with more than 5 minutes
of chest pain and ST-segment depression and/or elevated
troponin T or I concentration and in whom early (less than 48
hours) revascularization was not intended to be conducted.
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All received ASA and either unfractionated heparin (UFH) or
LMWH. They were randomized to placebo, an abciximab
bolus and 24-hour infusion, or an abciximab bolus and
48-hour infusion. The primary end point, death or MI at 30
days, occurred in 8.0% of patients given placebo, 8.2% given
24-hour abciximab, and 9.1% given 48-hour abciximab,
differences that were not statistically significant. At 48 hours,
death occurred in 0.3%, 0.7%, and 0.9% in these groups,
respectively (placebo versus abciximab 48 hours, P0.008).
The lack of benefit of abciximab was observed in most
subgroups, including patients with elevated concentrations of
troponin who were at higher risk. Although the explanation
for these results is not clear, they indicate that abciximab, at
least at the dosing regimen used in GUSTO IV-ACS, is not
indicated in the management of patients with UA or NSTEMI
in whom an early invasive management strategy is not
planned.
In the PRISM-PLUS trial, 1069 patients did not undergo
early PCI. Although tirofiban treatment was associated with a
lower incidence of death, MI or death, and MI or refractory
ischemia at 30 days, these reductions were not statistically
significant.19 In a high-risk subgroup of these patients not
undergoing PCI (TIMI risk score greater than or equal to 4),3
tirofiban appeared to be beneficial whether they underwent
PCI (odds ratio [OR] 0.60, 95% CI 0.35 to 1.01) or not (OR
0.69, 95% CI 0.49 to 0.99). However, no benefit was
observed in the patients at lower risk.6 In the PURSUIT trial,
eptifibatide reduced the incidence of death or MI from 15.7%
to 14.2% (RR 0.91; 95% CI 0.79 to 1.00; P0.032).20
Boersma et al performed a meta-analysis of GP IIb/IIIa
antagonists in all 6 large, randomized, placebo-controlled
trials (including GUSTO IV-ACS,18 which involved 31 402
patients with UA/NSTEMI who were not routinely scheduled
to undergo coronary revascularization.21 A small reduction in
the odds of death or MI in the active treatment arm (11.8%
versus 10.8%; OR 0.91, 95% CI 0.84 to 0.98; P0.015) was
observed. Unexpectedly, no benefit was observed in women
(test for interaction between treatment assignment and gen-
der, P less than 0.0001). However, women with positive
troponins derived a treatment benefit that was similar to men.
In the meta-analysis, reductions in the end points of death or
nonfatal MI considered individually did not achieve statistical
significance.
Although not scheduled for coronary revascularization
procedures, 11 965 of the 31 402 patients (38%) actually
underwent PCI or CABG within 30 days, and in this sub-
group, the OR for death or MI in patients assigned to GP
IIb/IIIa antagonists was 0.89 (95% CI 0.80 to 0.98). In the
other 19 416 patients who did not undergo coronary revascu-
larization, the OR for death or MI in the GP IIb/IIIa group
was 0.95 (95% CI 0.86 to 1.05, PNS). Major bleeding
complications were increased in the GP IIb/IIIa antagonist-
treated group compared with those who received placebo
(1.4% versus 2.4%, P less than 0.0001). The authors con-
cluded that in patients with UA/NSTEMI who were not
routinely scheduled for early revascularization and who were
at high risk of thrombotic complications, “treatment with a
GP IIb/IIIa inhibitor might therefore be considered.” Thus,
GP IIb/IIIa inhibitors are of benefit in high-risk patients with
UA/NSTEMI, and their administration, in addition to ASA
and heparin, to patients in whom catheterization and PCI are
planned received a Class I recommendation. These agents are
of questionable benefit in patients who do not undergo PCI.
However, the revised guidelines recommend broader indica-
tions for a routine invasive strategy (see following text).
Thus, clopidogrel (in addition to aspirin and heparin or low
molecular weight heparin) is recommended for patients with
UA/NSTEMI in whom a noninterventional approach is
planned (Class I recommendation). In patients in whom an
interventional approach is planned, a GP IIb/IIIa inhibitor (in
addition to aspirin and heparin or low molecular weight
heparin) is recommended (Class I recommendation). No
head-to-head comparison of clopidogrel, a GP IIb/IIIa inhib-
itor, and their combination has been reported. The addition of
a GP IIb/IIIa inhibitor to a subset of patients in the CURE trial
who were receiving aspirin, clopidogrel, and heparin ap-
peared to be well tolerated, and current practice frequently
involves the use of this combination of drugs. However, until
further information on the safety and efficacy of such
quadruple therapy becomes available, a Class IIa recommen-
dation is made for the addition of a GP IIb/IIIa inhibitor for
patients with UA/NSTEMI who are receiving aspirin, clopi-
dogrel, and unfractionated or low molecular weight heparin
and who are referred for an invasive strategy. A Class I
recommendation is made for a GP IIb/IIIa inhibitor at the
time of PCI in patients receiving heparin and aspirin. Specific
updated recommendations for the use of antiplatelet regimens
in the revised guidelines are as follows:
Class I
1. Antiplatelet therapy should be initiated promptly.
ASA should be administered as soon as possible
after presentation and continued indefinitely.
(Level of Evidence: A)
2. Clopidogrel should be administered to hospital-
ized patients who are unable to take ASA because
of hypersensitivity or major gastrointestinal intol-
erance. (Level of Evidence: A)
*3. In hospitalized patients in whom an early nonin-
terventional approach is planned, clopidogrel
should be added to ASA as soon as possible on
admission and administered for at least 1 month
(Level of Evidence: A), and for up to 9 months.
(Level of Evidence: B)
*4. A platelet GP IIb/IIIa antagonist should be ad-
ministered, in addition to ASA and heparin, to
patients in whom catheterization and PCI are
planned. The GP IIb/IIIa antagonist may also be
administered just prior to PCI. (Level of Evidence:
A)
*†5. In patients for whom a PCI is planned and who
are not at high risk for bleeding, clopidogrel
should be started and continued for at least 1
month (Level of Evidence: A) and for up to 9
months. (Level of Evidence: B)
*6. In patients taking clopidogrel in whom elective
CABG is planned, the drug should be withheld for
5 to 7 days. (Level of Evidence: B)
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Class IIa
*1. Eptifibatide or tirofiban should be administered, in
addition to ASA and LMWH or UFH, to patients
with continuing ischemia, an elevated troponin, or
with other high-risk features in whom an invasive
management strategy is not planned. (Level of
Evidence: A)
*2. A platelet GP IIb/IIIa antagonist should be admin-
istered to patients already receiving heparin, ASA,
and clopidogrel in whom catheterization and PCI
are planned. The GP IIb/IIIa antagonist may also
be administered just prior to PCI. (Level of Evi-
dence: B)
Class IIb
*1. Eptifibatide or tirofiban, in addition to ASA and
LMWH or UFH, to patients without continuing
ischemia who have no other high-risk features and
in whom PCI is not planned. (Level of Evidence: A)
Class III
1. Intravenous fibrinolytic therapy in patients without
acute ST-segment elevation, a true posterior MI, or
a presumed new left bundle-branch block. (Level of
Evidence: A)
*2. Abciximab administration in patients in whom PCI
is not planned. (Level of Evidence: A)
*New indication, not included in September 2000
guidelines.
†Minor clarification different from full-text version on
web site.
Anticoagulant Therapy
The September 2000 guidelines1 reviewed the evidence re-
garding the use of intravenous UFH or subcutaneous LMWH.
It provided the following Class I recommendation:
“Parenteral anticoagulation with intravenous
UFH or subcutaneous LMWH should be added to
antiplatelet therapy with ASA or a thienopyridine.
(Level of Evidence: B)”
In the interim, a number of studies have appeared that
support the use of enoxaparin. In the EVET trial (Enoxaparin
VErsus Tinzaparin in the management of unstable coronary
artery disease), 2 LMWHs, enoxaparin and tinzaparin, ad-
ministered for 7 days, were compared in 438 patients with
UA/NSTEMI. A preliminary report stated that both the
recurrence of unstable angina and the need for revasculariza-
tion were significantly lower in the enoxaparin group.22
Because the level of anticoagulant activity cannot be easily
measured in patients given LMWH (eg, activated partial
thromboplastin time or activated clotting time), interventional
cardiologists have expressed concern about the substitution of
LMWH for UFH in patients scheduled for catheterization
with possible PCI. However, Collet et al23 have shown in a
small nonrandomized observation study in 293 patients that
PCI can be performed safely with UA/NSTEMI patients who
received the usual dose of enoxaparin. In NICE-1 (National
Investigators Collaborating on Enoxaparin), an observational
study, intravenous enoxaparin (1.0 mg/kg) was used in 828
patients undergoing elective PCI without an intravenous GP
IIb/IIIa antagonist.24 The rates of bleeding (1.1% major
bleeding and 6.2% minor bleeding in 30 days) were compa-
rable to those observed in historical controls with UFH.
An alternative approach is to use LMWH during the period
of initial stabilization and to withhold the dose on the
morning of the procedure. If an intervention is required and
more than 8 hours has elapsed since the last dose of LMWH,
UFH can be used for PCI according to usual practice patterns.
Because the anticoagulant effect of UFH can be more readily
reversed than that of LMWH, UFH is preferred in patients
likely to undergo CABG within 24 hours.
The September 2000 guidelines reflected concern regard-
ing the combined use of LMWH and GP IIb/IIIa antagonists.
Although the data are not definitive, it now appears that GP
IIb/IIIa antagonists can be used with LMWH. In the ACUTE
II (Anti-thrombotic Combination Using Tirofiban and Enox-
aparin II) study,25 UFH and enoxaparin were compared in
patients with UA/NSTEMI who were given tirofiban. The
frequencies of both major and minor bleeding were similar,
and there was a trend to fewer adverse events in the patients
given enoxaparin. A number of other open-label studies have
examined the safety of combining enoxaparin, with abcix-
imab, eptifibatide, or tirofiban in patients with UA/NSTEMI
who are treated with PCI or conservatively; of combining
enoxaparin with abciximab in patients undergoing elective
PCI26; and of combining dalteparin with abciximab in patients
with UA/NSTEMI who are treated conservatively and during
PCI.27 Although the majority of these studies relied on
historical controls, none suggested that the combination of
enoxaparin and a GP IIb/IIIa antagonist was associated with
excess bleeding, whether or not the patient also underwent
PCI.
Specific recommendations for the use of heparins in the
revised guidelines are as follows:
Class I
*1. Anticoagulation with subcutaneous LMWH or
intravenous UFH should be added to antiplatelet
therapy with ASA and/or clopidogrel. (Level of
Evidence: A)
Class IIa
*†1. Enoxaparin is preferable to UFH as an anticoag-
ulant in patients with UA/NSTEMI, in the absence
of renal failure and unless CABG is planned
within 24 hours. (Level of Evidence: A)
*New indication, not included in the September 2000
guidelines.
†Minor clarification different from full-text version on
web site.
Early Conservative vs Early
Invasive Strategies
The September 2000 guidelines indicated that 2 different
treatment strategies, termed “early conservative” and “early
invasive,” may be used in patients with UA/NSTEMI.1 In the
early conservative strategy, coronary angiography is reserved
for patients with evidence of recurrent ischemia (angina at
rest or with minimal activity or dynamic ST-segment
changes) or a strongly positive stress test despite vigorous
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medical therapy. In the early invasive strategy, patients
without clinically obvious contraindications to coronary re-
vascularization are routinely recommended for coronary an-
giography and angiographically directed revascularization, if
possible.
Several trials comparing these 2 strategies were reviewed,
but greatest attention was paid to the then-most-recent trial,
FRISC II (Fragmin and Fast Revascularization during InSta-
bility in Coronary artery disease II).28 At 1 year, the mortality
rate in the invasive strategy group was 2.2% compared with
3.9% in the noninvasive strategy group (P0.016).29 How-
ever, in FRISC II, the invasive strategy involved treatment for
an average of 6 days in the hospital with LMWH, ASA,
nitrates, and beta-blockers before coronary angiography, an
approach that would be difficult to adopt in US hospitals.
In the interim, the TACTICS-TIMI 18 trial was reported.7
In this trial, 2220 patients with UA or NSTEMI were treated
with ASA, heparin, and the GP IIb/IIIa antagonist tirofiban.
They were then randomized to an early invasive strategy with
routine coronary angiography within 48 hours followed by
revascularization if the coronary anatomy was deemed suit-
able, or to a more conservative strategy. In the latter,
catheterization was performed only if the patient had recur-
rent ischemia or a strongly positive stress test. Death, myo-
cardial (re)infarction, or rehospitalization for an acute coro-
nary syndrome at 6 months occurred in 19.4% of patients
assigned to the conservative strategy versus 15.9% assigned
to the invasive strategy (OR 0.78; 95% CI 0.62 to 0.97;
P0.025). Occurrence of death or MI was also reduced at 6
months (9.5% versus 7.3%; P less than 0.05). The beneficial
effects on outcome were particularly evident in medium- and
high-risk patients, as defined by an elevation of troponin T
greater than 0.01 ng/mL or of troponin I greater than 0.1
ng/mL, the presence of ST-segment deviation, or a TIMI risk
score greater than or equal to 3.7,30 In the absence of these
high-risk features, outcomes in patients assigned to the 2
strategies were similar. Rates of major bleeding were similar,
and lengths of hospital stay were reduced in patients assigned
to the invasive strategy. The benefits of the invasive strategy
were achieved at no significant increase in the cost of care
over the 6-month follow-up period.
Thus, both the FRISC II28,29 and TACTICS-TIMI 187,30
trials, the 2 most recent trials comparing invasive versus
conservative strategies in patients with UA/NSTEMI, showed
a benefit in patients assigned to the invasive strategy. In
contrast to earlier trials, a large majority of patients undergo-
ing PCI in these 2 trials received coronary stents as opposed
to balloon angioplasty alone. In TACTICS-TIMI 18, treat-
ment included the GP IIb/IIIa antagonist tirofiban, which was
administered for an average of 22 hours before coronary
angiography. The routine use of the GP IIb/IIIa antagonist in
this trial may have eliminated the excess risk of early (within
7 days) acute MI in the invasive arm, an excess risk that was
observed in FRISC II and other trials in which there was no
routine “upstream” use of a GP IIb/IIIa antagonist. Therefore,
an invasive strategy is associated with a better outcome in
UA/NSTEMI patients at high risk who receive a GP IIb/IIIa
antagonist.7 Although the benefit of GP IIb/IIIa antagonists is
well established for patients with UA/NSTEMI who undergo
PCI, the optimum time of commencing these drugs—as early
as possible after presentation, ie, “upstream,” as in TACTICS
TIMI 18, or just before the PCI—has not been established.
Specific recommendations for the use of an invasive
strategy in the revised guidelines are as follows:
Class I
†1. An early invasive strategy in patients with UA/
NSTEMI without serious comorbidity and who
have any of the following high-risk indicators:
(Level of Evidence: A)
*(a) Recurrent angina/ischemia at rest or with
low-level activities despite intensive anti-ische-
mic therapy.
*(b) Elevated TnT or TnI
*(c) New or presumably new ST-segment depression
(d) Recurrent angina/ischemia with CHF symp-
toms, an S3 gallop, pulmonary edema, worsen-
ing rales, or new or worsening MR
(e) High-risk findings on noninvasive stress testing
(f) Depressed LV systolic function (eg, EF less than
0.40 on noninvasive study)
(g) Hemodynamic instability
(h) Sustained ventricular tachycardia
(i) PCI within 6 months
(j) Prior CABG
2. In the absence of any of these findings, either an
early conservative or an early invasive strategy may
be offered in hospitalized patients without contrain-
dications for revascularization. (Level of Evidence:
B)
*New indication, not included in the September 2000
guidelines.
†Minor clarification different from full-text version on
web site.
Risk Factor Modification
The September 2000 guidelines pointed out that despite the
overwhelming evidence for the benefits of beta-hydroxy-
beta-methylglutaryl-coenzyme A (HMG-CoA) reductase
(statin) therapy in patients with elevated low-density lipopro-
tein (LDL) cholesterol levels, almost no data existed about
the timing of initiation of therapy in patients with acute
coronary syndromes.1 Indeed, the secondary prevention trials
of stating specifically excluded patients with UA/NSTEMI in
the acute phase. Fewer than 300 patients had been entered
into the trials within 4 months of an acute coronary syndrome.
The Lipid-Coronary Artery Disease (L-CAD) study was a
small trial that randomized 126 patients with an acute
coronary syndrome to early treatment with pravastatin, alone
or in combination with cholestyramine or niacin, or to usual
care. At 24 months, the patients who received early aggres-
sive treatment had a lower incidence of clinical events (23%)
than the usual-care group (52%; P0.005).31 In the MIRACL
(Myocardial Ischemia Reduction with Aggressive Cholester-
ol Lowering) trial, 3086 patients were randomized to treat-
ment with an aggressive lipid-lowering regimen of atorvasta-
tin 80 mg per day or placebo 24 to 96 hours after an acute
coronary syndrome.32 At 16 weeks of follow-up, the primary
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end point of death, nonfatal MI, resuscitated cardiac arrest, or
recurrent severe myocardial ischemia was reduced from
17.4% in the placebo group to 14.8% in the atorvastatin group
(P0.048). There were no significant differences between
the 2 groups in the risk of the following individual end points:
death, nonfatal MI, cardiac arrest, or worsening heart failure;
however, there were fewer strokes and a lower risk of severe
recurrent ischemia in patients assigned to atorvastatin.
Although the evidence from these 2 trials of a beneficial
effect of predischarge initiation of lipid-lowering therapy is
not yet robust or definitive, observational studies support this
policy. In the Swedish Registry of Cardiac Intensive Care of
almost 20 000 patients, the adjusted relative risk of mortality
was 25% lower in patients in whom statin therapy was
initiated before hospital discharge.33 In addition, patients in
whom lipid-lowering therapy is begun in the hospital are
much more likely to be undergoing such therapy at a later
time. In one demonstration project, the Cardiovascular Hos-
pitalization Atherosclerosis Management Program
(CHAMP), the in-hospital initiation of lipid-lowering therapy
was associated with an increased percentage of patients
treated with statins 1 year later (from 10% to 91%) and with
a higher frequency of patients whose LDL cholesterol was
less than 100 mg/dL (from 6% to 58%).34 Although additional
trials are ongoing, there appear to be no adverse effects and
substantial advantages to the initiation of lipid-lowering
therapy before hospital discharge.35–37 Such early initiation of
therapy has also been recommended in the third report of the
National Cholesterol Education Program (NCEP III), which
also raised the threshold of high-density lipoprotein choles-
terol concentration that required therapy.38 Similar consider-
ations apply to the early initiation of statin therapy following
PCI. In the Lescol Intervention Prevention Study (LIPS),
1669 patients were randomized to receive 80 mg fluvastatin
or placebo, beginning two days after PCI. After a follow-up
of 3.9 years, the statin-treated group had a lower incidence of
clinical events (21.4%) than the placebo group (26.7%),
P0.01.39
In addition to maintaining the original Class I recommen-
dations for LDL cholesterol reduction, specific additional
recommendations for the use of lipid-lowering therapy in
UA/NSTEMI in the revised guidelines are as follows:
Class I
*1. A fibrate or niacin if high-density lipoprotein cho-
lesterol is less than 40 mg per dl, occurring as an
isolated finding or in combination with other lipid
abnormalities. (Level of Evidence: B)
Class IIa
*1. HMG-CoA reductase inhibitors and diet for LDL
cholesterol greater than 100 mg per dl begun 24 to
96 hours after admission and continued at hospital
discharge. (Level of Evidence: B)
*New indication, not included in the September 2000
guidelines.
Conclusions
These guidelines address the diagnosis and management of
patients with UA and the closely related condition NSTEMI.
These life-threatening disorders are a major cause of emer-
gency medical care and are responsible for more than 1.4
million hospitalizations annually in the United States.40
Nearly 60% of these admissions are among persons greater
than 65 years old, and almost half occur in women. In 1997,
there were 5 315 000 visits to US emergency departments for
the evaluation of chest pain and related symptoms.41
Because of the high incidence of UA/NSTEMI and the
seriousness of this condition (approximately 15% rate of
death or [re]infarction at 30 days),1,20 continued research in
this field is of the greatest importance. It is encouraging that
in the 21 months since the publication of the September 2000
guidelines, a considerable body of additional useful informa-
tion about these conditions has emerged. Indeed, the progress
between September 2000 and June 2002 equals that between
1994, when the first guidelines were published,42 and Sep-
tember 2000.
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